8-K: AbCellera Biologics Appoints EY as New Auditor

AbCellera Biologics Inc. announced the dismissal of KPMG LLP and the engagement of Ernst & Young LLP as its new independent registered public accounting firm, effective after the 2025 fiscal year audit.

Summary

• AbCellera Biologics Inc. dismissed KPMG LLP as its independent registered public accounting firm, effective following the completion of KPMG's audit for the fiscal year ending December 31, 2025, and the filing of the associated Annual Report on Form 10-K.
• The Audit Committee of the Board of Directors approved the dismissal on November 24, 2025.
• The company engaged Ernst & Young LLP (EY) as its new independent registered public accounting firm for the fiscal year ending December 31, 2026.
• EY's engagement is contingent upon the completion of their standard client acceptance and independence procedures and the execution of an engagement letter.
• The change in auditors was a result of the Audit Committee's ongoing oversight and a formal audit firm tender process initiated earlier in the year.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The change in auditor is a routine corporate governance matter, and the explicit statement that there were no disagreements with the outgoing auditor on accounting principles or practices is a positive sign, indicating no underlying financial reporting issues.

Positives

• The dismissal of KPMG LLP was not related to any disagreements on accounting principles or practices, financial statement disclosure, or auditing scope or procedure.
• KPMG's audit reports for the fiscal years ended December 31, 2024, and December 31, 2023, did not contain an adverse opinion, a disclaimer of opinion, or any qualifications or modifications.
• No reportable events, as defined in Item 304(a)(1)(v) of Regulation S-K, occurred during the fiscal years ended December 31, 2024, and December 31, 2023, or the subsequent interim period.

Future Outlook

The company anticipates KPMG LLP will complete its audit of the consolidated financial statements for the fiscal year ending December 31, 2025, and file the associated Annual Report on Form 10-K. Ernst & Young LLP is expected to serve as the independent registered public accounting firm for the fiscal year ending December 31, 2026, pending standard client acceptance and independence procedures.

Management Comments

• The Audit Committee initiated a formal audit firm tender process earlier this year as part of its ongoing oversight and assessment of the independent registered public accounting firm.

Industry Context

Changes in independent registered public accounting firms are a common practice among publicly traded companies, often occurring as part of routine corporate governance reviews or tender processes to ensure auditor independence, cost-effectiveness, and fresh perspectives. This move by AbCellera Biologics aligns with industry best practices for periodic auditor rotation.

Comparison to Industry Standards

• Many public companies periodically review their auditing arrangements, often every 5-10 years, to ensure optimal service and compliance, similar to practices seen at peers like Moderna or BioNTech in the biotech sector, though specific timelines vary.
• The absence of disagreements with the outgoing auditor, KPMG, regarding accounting principles or practices, is a positive indicator, aligning with the transparency standards expected in the industry, unlike situations where auditor changes are prompted by material disagreements, which can raise red flags for investors.
• Engaging a 'Big Four' firm like Ernst & Young LLP is standard for a company of AbCellera's size and public status, providing assurance of robust audit capabilities and global reach, comparable to the audit firms used by other major pharmaceutical and biotech companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The change is a routine governance matter with no disclosed negative implications, potentially enhancing confidence in financial reporting through a fresh audit perspective.
• Employees: No direct impact on employees is indicated by this administrative change.
• Customers/Suppliers: No direct impact on operational relationships with customers or suppliers is expected.
• Creditors: The continuity of a 'Big Four' auditor (EY replacing KPMG) maintains the credibility of financial statements, which is important for creditors assessing the company's financial health.

Next Steps

• KPMG LLP will complete its audit of the company's consolidated financial statements for the fiscal year ending December 31, 2025.
• KPMG LLP will file the company's Annual Report on Form 10-K for the fiscal year ending December 31, 2025.
• Ernst & Young LLP will complete its standard client acceptance and independence procedures.
• Ernst & Young LLP will execute an engagement letter with the company.

Key Dates

Recommendation

This filing details a routine change in the company's independent registered public accounting firm, from KPMG LLP to Ernst & Young LLP, following a formal tender process. Crucially, the company explicitly stated there were no disagreements with KPMG on accounting principles or practices, and KPMG's prior audit reports were unqualified. This indicates a healthy corporate governance practice rather than a red flag concerning financial reporting integrity. As such, this administrative change does not alter the fundamental investment thesis for AbCellera Biologics and is unlikely to have a significant impact on the share price. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial news.

Keywords

AbCellera Biologics, ABCL, Auditor Change, KPMG, Ernst & Young, EY, SEC Filing, 8-K, Corporate Governance, Financial Reporting